1.46
price down icon5.81%   -0.09
after-market After Hours: 1.43 -0.03 -2.05%
loading
Allogene Therapeutics Inc stock is traded at $1.46, with a volume of 2.90M. It is down -5.81% in the last 24 hours and down -25.13% over the past month. Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$1.55
Open:
$1.5
24h Volume:
2.90M
Relative Volume:
0.56
Market Cap:
$316.12M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-0.6887
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
-13.10%
1M Performance:
-25.13%
6M Performance:
-47.86%
1Y Performance:
-67.34%
1-Day Range:
Value
$1.39
$1.5019
1-Week Range:
Value
$1.39
$1.70
52-Week Range:
Value
$1.32
$4.45

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
Name
Allogene Therapeutics Inc
Name
Phone
(650) 457-2700
Name
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
Employee
361
Name
Twitter
@AllogeneTx
Name
Next Earnings Date
2025-03-04
Name
Latest SEC Filings
Name
ALLO's Discussions on Twitter

Compare ALLO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALLO
Allogene Therapeutics Inc
1.46 316.12M 95,000 -327.27M -239.25M -2.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-14-25 Upgrade Citizens JMP Mkt Perform → Mkt Outperform
Aug-08-24 Resumed Oppenheimer Outperform
May-31-24 Initiated Piper Sandler Overweight
Jan-05-24 Downgrade Guggenheim Buy → Neutral
Jan-05-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Dec-08-23 Initiated Citigroup Buy
Jun-26-23 Resumed Oppenheimer Outperform
Mar-21-23 Initiated Bernstein Mkt Perform
Jan-24-23 Upgrade JP Morgan Neutral → Overweight
Jan-06-23 Upgrade Robert W. Baird Neutral → Outperform
Dec-12-22 Downgrade BofA Securities Buy → Underperform
Aug-10-22 Downgrade Raymond James Outperform → Mkt Perform
Jul-15-22 Upgrade Goldman Neutral → Buy
Jun-03-22 Initiated Robert W. Baird Neutral
Feb-28-22 Reiterated B. Riley Securities Buy
Oct-20-21 Initiated Cowen Outperform
Oct-08-21 Downgrade Goldman Buy → Neutral
Oct-08-21 Downgrade Stifel Buy → Hold
Sep-23-21 Upgrade Raymond James Mkt Perform → Outperform
Jun-21-21 Resumed Jefferies Buy
May-20-21 Upgrade Truist Hold → Buy
May-14-21 Initiated B. Riley Securities Buy
Jan-26-21 Upgrade Stifel Hold → Buy
Dec-10-20 Resumed H.C. Wainwright Buy
Nov-24-20 Initiated BofA Securities Buy
Oct-23-20 Initiated RBC Capital Mkts Outperform
Jun-01-20 Downgrade Raymond James Outperform → Mkt Perform
May-29-20 Reiterated H.C. Wainwright Buy
May-19-20 Upgrade ROTH Capital Neutral → Buy
May-15-20 Upgrade Guggenheim Neutral → Buy
May-14-20 Reiterated H.C. Wainwright Buy
May-14-20 Downgrade SunTrust Buy → Hold
Apr-13-20 Initiated SunTrust Buy
Mar-13-20 Initiated H.C. Wainwright Buy
Mar-05-20 Initiated Stifel Hold
Feb-24-20 Initiated Berenberg Hold
Dec-18-19 Initiated JMP Securities Mkt Outperform
Nov-04-19 Initiated Canaccord Genuity Buy
Aug-09-19 Initiated BTIG Research Buy
Jun-05-19 Initiated ROTH Capital Neutral
May-31-19 Initiated Guggenheim Neutral
May-23-19 Initiated Stifel Hold
Mar-29-19 Initiated Piper Jaffray Overweight
View All

Allogene Therapeutics Inc Stock (ALLO) Latest News

pulisher
Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Allogene Therapeutics CEO sells $91,469 in stock By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Allogene Therapeutics CEO sells $91,469 in stock - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Allogene Therapeutics Executives Sell Shares for Tax Obligations - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Renal Cancer Clinical Pipeline | 75+ Companies, Including - openPR.com

Mar 18, 2025
pulisher
Mar 17, 2025

7th Annual Allogeneic Cell Therapies Summit - pharmaphorum

Mar 17, 2025
pulisher
Mar 17, 2025

Allogene Therapeutics' SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Allogene Therapeutics’ SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

Allogeneic T Cell Therapies Market Set For 9.8% Growth, Reaching $1.9 Billion By 2029 - WhaTech

Mar 17, 2025
pulisher
Mar 16, 2025

Allogene upgraded at Citizens after Q4 update - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 15, 2025
pulisher
Mar 15, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 15, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... By GuruFocus - Investing.com Canada

Mar 14, 2025
pulisher
Mar 14, 2025

Citizens Capital Markets Upgrades Allogene Therapeutics (ALLO) - Nasdaq

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... - Yahoo

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlight - GuruFocus.com

Mar 14, 2025
pulisher
Mar 14, 2025

Citi maintains Buy on Allogene stock with $8 price target By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene stock upgraded at Citizens post Q4 (ALLO:NASDAQ) - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

Citi maintains Buy on Allogene stock with $8 price target - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene's Q4 Loss Narrower Than Expected, Revenues Nil - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Allogene Therapeutics: Q4 Earnings Snapshot - The Wilton Bulletin

Mar 14, 2025
pulisher
Mar 13, 2025

Earnings call transcript: Allogene’s Q4 2024 earnings beat expectations By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Earnings call transcript: Allogene’s Q4 2024 earnings beat expectations - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Allogene Therapeutics Inc Q4 Loss Per Share $0.28 -March 13, 2025 at 05:32 pm EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Allogene Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Estimates; Revenue Falls Short - GuruFocus.com

Mar 13, 2025
pulisher
Mar 13, 2025

Allogene Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

ALLOGENE THERAPEUTICS Earnings Results: $ALLO Reports Quarterly Earnings - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

Allogene Therapeutics: Q4 Earnings Snapshot -March 13, 2025 at 05:05 pm EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 08, 2025

Allogene Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 05, 2025

CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - Yahoo Finance

Mar 05, 2025
pulisher
Mar 05, 2025

CAR T-cell Therapy Clinical Trial Pipeline Experiences - GlobeNewswire

Mar 05, 2025
pulisher
Mar 03, 2025

Foresight Diagnostics expands Allogene partnership - BizWest

Mar 03, 2025
pulisher
Mar 03, 2025

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

When Will Allogene Reveal Its CAR T Progress? Key Earnings Date Set - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Allogene Therapeutics Schedules Conference Call and Webcast for Q4 and Full Year 2024 Financial Results on March 13, 2025 - Nasdaq

Mar 03, 2025
pulisher
Feb 27, 2025

Foresight Diagnostics Expands Strategic Partnership with Allogene Therapeutics to Advance Joint Development Activities Outside of the U.S. Across Europe, UK, Canada and Australia - The Malaysian Reserve

Feb 27, 2025
pulisher
Feb 27, 2025

Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise - MSN

Feb 27, 2025
pulisher
Feb 26, 2025

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities (NASDAQ:ALLO) - Seeking Alpha

Feb 26, 2025
pulisher
Feb 26, 2025

Allogene Expands Partnership With Foresight Diagnostics To Advance Cema-Cel Development Globally - Nasdaq

Feb 26, 2025
pulisher
Feb 26, 2025

Allogene Therapeutics Announces Participation in March Investor Conference - The Manila Times

Feb 26, 2025

Allogene Therapeutics Inc Stock (ALLO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):